John E. Elicker | Bristol-Myers Squibb Co. |
Giovanni Caforio | Bristol-Myers Squibb Co. |
Charles A. Bancroft | Bristol-Myers Squibb Co. |
Thomas J. Lynch, Jr. | Bristol-Myers Squibb Co. |
Murdo Gordon | Bristol-Myers Squibb Co. |
Umer Raffat | Evercore ISI |
Jami Rubin | Goldman Sachs & Co. LLC |
Andrew S. Baum | Citigroup Global Markets Ltd. |
Seamus Fernandez | Leerink Partners LLC |
Tim Anderson | Sanford C. Bernstein & Co. LLC |
Chris Schott | JPMorgan Securities LLC |
David R. Risinger | Morgan Stanley & Co. LLC |
Vamil K. Divan | Credit Suisse Securities (NYSE:USA) LLC |
Gregg Gilbert | Deutsche Bank Securities, Inc. |
Geoffrey Meacham | Barclays Capital, Inc. |
Good day and welcome to the Bristol-Myers Squibb 2017 Third Quarter Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. John Elicker, Senior Vice President, Corporate Affairs and Investor Relations. Please go ahead, sir.